Search
for
Sort by
Research 151–180 of 1000+
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- The Glypican-1/HGF/C-Met and Glypican-1/VEGF/VEGFR2 Ternary Complexes Regulate Hair Follicle Angiogenesis
- Amphiregulin in Fibrotic Diseases and Cancer
- Functional characterization of OR51B5 and OR1G1 in human lung epithelial cells as potential drug targets for non-type 2 lung diseases
- Metabolic pathways of eicosanoids—derivatives of arachidonic acid and their significance in skin
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Integrative Analysis of the Metabolome and Transcriptome Reveals the Mechanism Underlying Differences in Skin Development Between the New Zealand Rabbit and the Rex Rabbit
- Unravelling the molecular basis for symbiotic signal transduction in legumes
- Identification of key genes and signaling pathways related to Hetian sheep wool density by RNA-seq technology
- Heat-killed Lacticaseibacillus paracasei GMNL-653 ameliorates human scalp health by regulating scalp microbiome
- Genomic prediction and genome-wide association studies of morphological traits and distraction index in Korean Sapsaree dogs
- Bee Venom Stimulates Growth Factor Release from Adipose-Derived Stem Cells to Promote Hair Growth
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- The Roles of Exosomes in Regulating Hair Follicle Growth
- Research Progress of Extracellular Vesicles-Loaded Microneedle Technology
- Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Protein profiling of forehead epidermal corneocytes distinguishes frontal fibrosing from androgenetic alopecia
- The JAK/STAT signaling pathway: from bench to clinic
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- An Overview of the Health Benefits, Extraction Methods and Improving the Properties of Pomegranate
- Opposing impacts on healthspan and longevity by limiting dietary selenium in telomere dysfunctional mice
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- JAK inhibition decreases the autoimmune burden in Down syndrome
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Under Development JAK Inhibitors for Dermatologic Diseases
- The significance of the apelinergic system in doxorubicin-induced cardiotoxicity